Efficacy and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation across BMI categories: a systematic review and meta-analysis
Objectives Concerns have arisen recently over the relationship between body mass index
(BMI) and outcomes in atrial fibrillation (AF) patients with direct oral anticoagulants (DOACs) …
(BMI) and outcomes in atrial fibrillation (AF) patients with direct oral anticoagulants (DOACs) …
Outcomes of direct oral anticoagulants in atrial fibrillation patients across different body mass index categories
Objectives This study sought to evaluate direct oral anticoagulant (DOAC) outcomes (vs.
warfarin) in patients with atrial fibrillation (AF) across body mass index (BMI) categories …
warfarin) in patients with atrial fibrillation (AF) across body mass index (BMI) categories …
Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and low body weight
Background: It is unclear whether the overall effectiveness and safety of direct oral
anticoagulants (DOACs) are consistent in patients with nonvalvular atrial fibrillation (AF) and …
anticoagulants (DOACs) are consistent in patients with nonvalvular atrial fibrillation (AF) and …
Comparative effectiveness and safety of direct oral anticoagulants in obese patients with atrial fibrillation
Background Unlike warfarin direct oral anticoagulants (DOACs) are administered in fixed
doses, which raises concerns of its effectiveness on larger patients. Data from randomized …
doses, which raises concerns of its effectiveness on larger patients. Data from randomized …
Comparing the efficacy and safety of direct oral anticoagulants with warfarin in the morbidly obese population with atrial fibrillation
K Kido, S Ngorsuraches - Annals of Pharmacotherapy, 2019 - journals.sagepub.com
Background: The International Society of Thrombosis and Haemostasis recommends
avoiding direct oral anticoagulants (DOACs) in morbidly obese patients with a body mass …
avoiding direct oral anticoagulants (DOACs) in morbidly obese patients with a body mass …
[HTML][HTML] Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and …
Essentials• The association of body weight and patient‐important outcomes remains
unknown.• Phase III randomized controlled trials of direct oral anticoagulants (DOACs) were …
unknown.• Phase III randomized controlled trials of direct oral anticoagulants (DOACs) were …
Is There an Obesity Paradox for Outcomes in Atrial Fibrillation? A Systematic Review and Meta-Analysis of Non–Vitamin K Antagonist Oral Anticoagulant Trials
M Proietti, E Guiducci, P Cheli, GYH Lip - Stroke, 2017 - Am Heart Assoc
Background and Purpose—Obesity is a risk factor for all-cause and cardiovascular death
but, despite this, an inverse relationship between overweight or obesity and a better …
but, despite this, an inverse relationship between overweight or obesity and a better …
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial
G Boriani, CT Ruff, JF Kuder, M Shi… - European heart …, 2019 - academic.oup.com
Aims To investigate the relationship between body mass index (BMI) and outcomes in
patients with atrial fibrillation (AF). Methods and results In the ENGAGE AF-TIMI 48 trial …
patients with atrial fibrillation (AF). Methods and results In the ENGAGE AF-TIMI 48 trial …
Edoxaban versus warfarin in patients with atrial fibrillation at the extremes of body weight: an analysis from the ENGAGE AF-TIMI 48 trial
G Boriani, CT Ruff, JF Kuder, M Shi… - Thrombosis and …, 2021 - thieme-connect.com
Background The effects of anticoagulants at extremes of body weight (BW) are not well
described. The aim of this study was to analyze the pharmacokinetics/pharmacodynamics …
described. The aim of this study was to analyze the pharmacokinetics/pharmacodynamics …
Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants
Background There is a paucity of evidence regarding the effects of non-vitamin K antagonist
oral anticoagulants (NOACs) in underweight patients with atrial fibrillation (AF). Objective …
oral anticoagulants (NOACs) in underweight patients with atrial fibrillation (AF). Objective …